Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lonidamine SCHEMBL29351122 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| Lonidamine SCHEMBL29350056 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| Lonidamine SCHEMBL28075715 | 0.93 | CYP1A2 (0.87) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| Lonidamine SCHEMBL28086501 | 0.92 | CYP1A2 (0.85) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| Lonidamine SCHEMBL5483035 | 0.91 | CYP1A2 (0.83) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL31566279 | 0.90 | CYP1A2 (0.82) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL14584151 | 0.90 | CYP1A2 (0.82) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL21121979 | 0.90 | CYP1A2 (0.82) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL30949037 | 0.90 | CYP1A2 (0.81) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL1051466 | 0.90 | CYP1A2 (0.81) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 31492 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080068-A | Mitochondria-targeted lonidamine and cinnamaldehyde coupled prodrug as well as preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075505-A | Ternary nanoparticle and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| EP-0642799-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| US-5260327-A | Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1993-11-09 | — | — | US | claimed |
| EP-0172721-B1 | USE OF PHLORIZIN OR ITS DERIVATIVES IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF CANCER | Leveen, Harry H. (US) | 1993-03-03 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| US-4840939-A | Treatment of cancer with phlorizin and its derivatives | LEVEEN HARRY H (US) | 1989-06-20 | — | — | US | claimed |
| EP-0291151-A1 | Compositions comprising phlorizin derivatives for treatment of cancer | Leveen, Harry H. (US) | 1988-11-17 | — | — | EP | claimed |
| US-4684627-A | Treatment of cancer with phlorizin and its derivatives | MEDICINAL DEVELOPMENTS,INC. | 1987-08-04 | — | — | US | claimed |
| EP-0172721-A2 | Use of phlorizin or its derivatives in combination with a chemotherapeutic agent for the treatment of cancer | Leveen, Harry H. (US) | 1986-02-26 | — | — | EP | claimed |
| US-4282237-A | Method with substituted 1-benzyl-1H-indazole-3-carboxylic acids for interrupting pregnancy in mammals | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1981-08-04 | — | — | US | claimed |